Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 115,578,968
  • Shares Outstanding, K 2,443,530
  • Annual Sales, $ 16,967 M
  • Annual Income, $ 5,792 M
  • 36-Month Beta 0.66
  • Price/Sales 6.75
  • Price/Cash Flow 18.26
  • Price/Book 14.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.61
  • Number of Estimates 1
  • High Estimate 0.61
  • Low Estimate 0.61
  • Prior Year 0.62
  • Growth Rate Est. (year over year) -1.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.62 +3.71%
on 08/10/18
51.64 -6.37%
on 07/26/18
-1.53 (-3.07%)
since 07/13/18
3-Month
44.28 +9.20%
on 06/12/18
51.64 -6.37%
on 07/26/18
-1.63 (-3.26%)
since 05/14/18
52-Week
44.28 +9.20%
on 06/12/18
58.37 -17.17%
on 01/23/18
+3.02 (+6.66%)
since 08/14/17

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

AZN : 38.98 (-0.10%)
NVO : 48.35 (+2.22%)
JNJ : 129.50 (-0.55%)
MRK : 66.46 (-0.39%)
AGN : 184.46 (+0.10%)
EDIT : 29.60 (+0.82%)
BMY : 59.96 (+0.91%)
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.

AZN : 38.98 (-0.10%)
NVO : 48.35 (+2.22%)
JNJ : 129.50 (-0.55%)
MRK : 66.46 (-0.39%)
AGN : 184.46 (+0.10%)
EDIT : 29.60 (+0.82%)
BMY : 59.96 (+0.91%)
Novo Nordisk A/S Sponsored ADR Class B to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Novo Nordisk A/S Sponsored ADR Class B (NYSE: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 1:00 PM...

NVO : 48.35 (+2.22%)
Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates

Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.

NVO : 48.35 (+2.22%)
MRK : 66.46 (-0.39%)
LLY : 102.44 (unch)
GILD : 77.31 (+0.18%)
Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 4% in local currencies in the first six months of 2018

Sales decreased by 5% in Danish kroner and increased by 4% in local currencies to DKK 54.3 billion.

NVO : 48.35 (+2.22%)
BMY vs. NVO: Which Stock Is the Better Value Option?

BMY vs. NVO: Which Stock Is the Better Value Option?

NVO : 48.35 (+2.22%)
BMY : 59.96 (+0.91%)
Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label

Lilly (LLY) updates Trulicity's label to include data from a new study on patients with type II diabetes suffering from moderate to severe chronic kidney disease.

GHDX : 52.93 (-1.51%)
NVO : 48.35 (+2.22%)
LLY : 102.44 (unch)
VNDA : 21.60 (+0.70%)
LLY vs. NVO: Which Stock Is the Better Value Option?

LLY vs. NVO: Which Stock Is the Better Value Option?

NVO : 48.35 (+2.22%)
LLY : 102.44 (unch)
LLY vs. NVO: Which Stock Is the Better Value Option?

LLY vs. NVO: Which Stock Is the Better Value Option?

NVO : 48.35 (+2.22%)
LLY : 102.44 (unch)
The Shared Services and Outsourcing Network Presents Nordic Business Transformation: Nordic BT 2018 Is Transforming the Back-offices of the Future

Change or die is the message for the day, transformation will be the defining factor in the success of future businesses. Nordic Business Transformation 2018 (Nordic BT) aims to bring together experts...

NVO : 48.35 (+2.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade NVO with:

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 48.91
1st Resistance Point 48.63
Last Price 48.35
1st Support Level 48.09
2nd Support Level 47.83

See More

52-Week High 58.37
Fibonacci 61.8% 52.99
Fibonacci 50% 51.32
Fibonacci 38.2% 49.66
Last Price 48.35
52-Week Low 44.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar